冠心病患者应用瑞舒伐他汀与阿托伐他汀治疗的药学疗效对比

Pharmacological Effect Comparison Between Rosuvastatin and Atorvastatin in Treatment of Coronary Heart Disease Patients

目的探讨冠心病采取瑞舒伐他汀和阿托伐他汀的临床疗效。方法将2021年1月—2023年2月本院接诊的冠心病患者分组研究,将上述患者取随机数字表法分成对照组(n=27例,接受阿托伐他汀治疗),观察组(n=28例,接受瑞舒伐他汀治疗)。将患者心功能和血脂差异以及治疗有效率进行对比。结果心功能指标在治疗前无统计学意义(P>0.05);心功能治疗后均改善,观察组改善程度更优,组间差异有统计学意义(P<0.05)。治疗前,血脂水平在组间患者间不具有统计学意义(P>0.05);治疗后,组间患者血脂水平均改善,观察组患者TC指标、TG指标、LDL-C指标、HDL-C指标较对照组指标更优,差异有统计学意义(P<0.05)。观察组治疗有效率显著高于对照组,差异有统计学意义(P<0.05)。结论瑞舒伐他汀在冠心病的诊疗中效果更为确切,在改善患者心功能和血脂中有重要作用,治疗手段值得推广。

Objective To explore clinical effect of rosuvastatin and atorvastatin for coronary heart disease.Methods The paper chose patients with coronary heart disease admitted to our hospital from January 2021 to February 2023,and divided them into two groups randomly for research.Control group(n=27 cases)was treated with atorvastatin treatment,and observation group(n=28 cases)with rosuvastatin treatment.Difference of cardiac function and blood lipids,curative effect was compared.Results There was no statistically significant difference in cardiac function indicators before treatment(P>0.05).After treatment,cardiac function improved between groups,that of observation group was improved better(P<0.05).Before treatment,there was no statistically significant difference in blood lipid levels between groups(P>0.05).After treatment,blood lipid levels in both groups improved.TC,TG,LDL-C,and HDL-C indicators in observation group were better than control group(P<0.05),difference was statistically significant.Effective rate of tre atment in observation group was significantly higher than control group,(P<0.05),data difference was statistically significant.Conclusion Rosuvastatin is more effective in diagnosis and treatment of coronary heart disease,and plays an important role in heart function and blood lipids improvement o f patients,which is worthy promoting.